| Midbrain Organoid Dopaminergic Neurons | |
|---|---|
| Lineage | iPSC > Neural Progenitor > Midbrain Organoid > DA Neuron |
| Markers | TH, DAT, GIRK2, PITX3, LMX1A, FOXA2, EN1 |
| Brain Regions | Substantia Nigra pars compacta, Ventral Tegmental Area |
| Disease Relevance | Parkinson's Disease, Dopamine Dysregulation Syndrome |
Midbrain Organoid Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Midbrain organoid dopaminergic neurons are specialized neurons generated within midbrain organoids that model the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). These neurons produce dopamine, express tyrosine hydroxylase (TH) and the dopamine transporter (DAT), and exhibit the electrophysiological properties characteristic of authentic midbrain dopaminergic neurons[1][2].
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000700 | dopaminergic neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000700 | dopaminergic neuron | Medium |
Midbrain dopaminergic (mDA) neuron differentiation follows developmental cues:
iPSC-derived mDA neurons from PD patients reveal:
Clinical trials using mDA neuron transplantation for PD:
Testing of:
The study of Midbrain Organoid Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kriks et al. Floor plate-derived dopaminergic neurons from embryonic stem cells (2011). 2011. ↩︎
Jönsson et al. Defining the specification of human midbrain dopaminergic neurons (2019). 2019. ↩︎
Schultz et al. Parkinson's disease: genetic models and neurobiology (2018). 2018. ↩︎
Barker et al. Cell-based therapy for Parkinson's disease (2017). 2017. ↩︎